
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+2
September 30, 2014 - Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheons biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees. Please visit the Patheon LinkedIn page to learn more about our expanded capabilities and to follow Patheon. Visit our website at http://www.Patheon.com
Cgmp drug substance biomanufacturing,mammalian cell culture,process development,contract development and manufacturing,single-use and stainless steel technologies,clinical and commercial biomanufacturing,and aseptic fill-finish
Gallus biopharmaceuticals operates in the Biotechnology research industry.
Gallus biopharmaceuticals's revenue is 11m - 100m
Gallus biopharmaceuticals has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.